- Aprea Therapeutics has filed to raise $86 million in an IPO, although the final figure may differ.
- The company is advancing treatment programs for MDS and AML cancers.
- APRE expects topline readout for its lead program in 2H 2020.
- Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Aprea Therapeutics (APRE) has filed to raise gross proceeds of up to $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing cancer therapeutics that reactivate mutant p53 tumor suppressor protein.
APRE is in Phase 3 trials for its lead candidate with an expected next potential major milestone in the second half of 2020.
I’ll provide an update when we learn more IPO details from management.
Company & Technology
Boston, Massachusetts-based Aprea was founded in 2003 with a focus on developing cancer therapeutics that activate the reactive mutant p53 tumor suppressor protein, expressed by the TP53 gene which management claims is the most commonly mutated gene in cancer.
Management is headed by President, CEO and Director Christian S. Schade, who has been with the firm since 2016 was previously CEO of Novira Therapeutics (JNJ).
Aprea’s lead drug candidate APR-246 is a small-molecule p53 reactivator in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes [MDS] and acute myeloid leukemia [AML].
Management believes that due to p53’s function to sense DNA damage and induce cell cycle arrest, DNA damage repair, senescence and cellular apoptosis, as well as its high incidence in cancer patients, mutant p53 represents an attractive therapeutic target that could significantly improve patients’ lives.
The firm has received Orphan Drug and Fast Track designations from the US FDA for MDS as well as an Orphan Drug designation from the EU EMA for MDS, AML and ovarian cancer.
AR-246 is currently being evaluated in a pivotal Phase 3 trial with azacitidine for frontline treatment of TP53-mutant MDS and management expects initial data in H2 2020.

